Exodus Point Capital Management, LP Acelrx Pharmaceuticals Inc Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$0.93 - $1.51 $52,906 - $85,902	-56,889 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.03 - $1.7 $58,595 - $96,711	56,889 New	56,889 $79,000
Q1 2021 May 17, 2021	SELL	$1.25 - $2.77 $40,525 - $89,803	-32,420 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.18 - $1.98 $38,255 - $64,191	32,420 New	32,420 $40,000
Q2 2019 Aug 14, 2019	SELL	$2.1 - $3.93 $318,998 - $596,982	-151,904 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.35 - $3.83 $208,219 - $339,353	88,604 Added 139.97%	151,904 $529,000
Q4 2018 Feb 14, 2019	BUY	$2.13 - $4.8 $134,829 - $303,840	63,300 New	63,300 $146,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.